[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-337590-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-337590-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","microrna-190b-targets-rfwd3-in-estrogen-receptorpositive-breast-cancer-research-article","MicroRNA-190b Targets RFWD3 in Estrogen Receptor–Positive Breast Cancer - Research Article","","Breast cancer is the most common cancer worldwide, and about 70% is estrogen receptor–positive (ER+). MicroRNA-190b (miR-190b) is reported to be upregulated in ER+ disease and previously shown to be hypomethylated, suggesting a regulatory role in its increased expression. Using patient/cohort data and ER+ cell line analyses, miR-190b targets and clinical relevance in breast cancer subtypes were investigated. Results identify RFWD3 as a miR-190b regulatory target with subtype-specific prognostic associations. ",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/microrna-190b-targets-rfwd3-in-estrogen-receptorpositive-breast-cancer-research-article/337590/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/microrna-190b-targets-rfwd3-in-estrogen-receptorpositive-breast-cancer-research-article/337590.png","ImageObject",300,407,{"name":42,"@type":43},"Lucas Martin","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main objective of the study on miR-190b in ER+ breast cancer?","Question",{"text":63,"@type":64},"The study aimed to further define the role of miR-190b in ER+ breast cancer and to identify its clinically relevant targets in breast cancer.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did the researchers identify miR-190b targets in ER+ breast cancer?",{"text":68,"@type":64},"They used Cancer Genome Atlas data for gene expression and clinical information, and used the ER+ cell line T-47D with biotin-labeled miR-190b immunoprecipitation followed by RNA sequencing; Western blot confirmed a target.",{"name":70,"@type":61,"acceptedAnswer":71},"What is the relationship between miR-190b, RFWD3 expression, and patient outcomes?",{"text":72,"@type":64},"miR-190b targets RFWD3, leading to lower RFWD3 protein expression. Lower RFWD3 is associated with better overall survival in Luminal A patients, while this association is not observed in Luminal B patients.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},337590,1791202352,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","MicroRNA-190b Targets RFWD3 in Estrogen Receptor– Positive Breast Cancer  \nElisabet Alexandra Frick1, Karen Kristjansdottir1,  \nSnaedís Ragnarsdottir1, Arnar Ingi Vilhjalmsson1, Maria Rose Bustos1, Linda Vidarsdottir1, Thorkell Gudjonsson2 and Stefan Sigurdsson1  \n1Department of Biochemistry and Molecular Biology, Cancer Research Laboratory, Biomedical Center, Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.  \n2Biotech Research & Innovation Centre, University of Copenhagen, Copenhagen, Denmark.  \nBreast Cancer: Basic and Clinical Research  \nVolume 18: 1–11  \n© The Author(s) 2024  \nArticle reuse guidelines: [sagepub.com/journals-permissions](sagepub.com/journals-permissions)[ ](sagepub.com/journals-permissions)[DOI: 10.1177/11782234241234771](DOI: 10.1177/11782234241234771)  \n|  |  |\n| --- | --- |\n| ABSTRACT\u003Cbr>BACkgRouND: In the year 2020, breast cancer was the most common form of cancer worldwide. Roughly 70% of breast cancers are estrogen receptor–positive (ER+) . MicroRNA-190b (miR-190b) has previously been reported to be upregulated in ER+ breast cancers . Previously, we have demonstrated that miR-190b is hypomethylated in ER+ breast cancers, potentially leading to its upregulation .\u003Cbr>oBjECTivES: To further study the role of miR-190b in ER+ breast cancer and to identify its clinically relevant targets in breast cancer.\u003Cbr>DESigN: Patient cohort and cell line–based RNA-sequencing analysis .\u003Cbr>METhoDS: The Cancer Genome Atlas was used to obtain gene expression data and clinical information on patients with breast cancer. To identify messenger RNA (mRNA) targets for miR-190b, the ER+ breast cancer cell line T-47D was used to immunoprecipitate biotin-labeled miR-190b followed by RNA sequencing. Western blot was used to confirm miR-190b target. Patient survival based on miR-190b and selected target was studied using the Cancer Genome Atlas .\u003Cbr>RESulTS: In this study, we confirm that miR-190b is overexpressed in breast cancer via differential expression analysis and show that high expression of miR-190b results in more favorable outcomes in Luminal A patients, hazard ratio (HR) = 0. 29, 95% confidence interval [CI] = 0.12-0.71, P = .0063. MicroRNA-190b target analysis identified RING finger and WD repeat domain 3 (RFWD3) as one of miR-190b regulatory targets in ER+ breast cancer. Survival analysis of RFWD3 showed that elevated levels result in poorer overall survival in patients with Luminal A breast cancer (HR = 2. 22, 95% CI = 1.33-3.71, P = . 002) . Gene ontology analysis of our sequencing results indicates that miR- 190b may have a role in breast cancer development and/or tumorigenesis and that it may be a suitable tool in characterization between the ER+ subtypes, Luminal A, and Luminal B.\u003Cbr>CoNCluSioNS: We show that miR-190b targets RFWD3 in ER+ breast cancers leading to lower RFWD3 protein expression . Low levels of RFWD3 are associated with better outcomes in patients with Luminal A breast cancer but not in patients with Luminal B breast cancer. These findings provide novel insights into miR-190b role in breast cancer and that its clinical relevance is subtype specific.\u003Cbr>PlAiN lANguAgE SuMMARy\u003Cbr>MicroRNA-190b targets RFWD3 in ER-positive Breast Cancer\u003Cbr>Breast cancer is the most common diagnosed type of cancer worldwide. Most of them, or 70%, overexpressed the estrogen receptor (ER) which can be targeted with drugs . MicroRNA-190b (miR-190b) is known to be overexpressed in these types of breast cancers, and we have shown that loss of DNA methylation within the genomic region of miR-190b occurs in these ER+ cancers as well, which potentially is the cause for its overexpression . We, therefore, aimed at understanding miR-190b further. To do so, we used a technique called immunoprecipitation to capture miR-190b targets and performed RNA sequencing to identify potential targets . Of the targets, we identified RFWD3 and performed a western blot to confirm whether it was a tru","cbCaijfQeyL64r39","https://ap.wps.com/l/cbCaijfQeyL64r39","pdf",2572257,11,"English","# Abstract\n## Background\n## Objectives\n## Design\n## Methods\n## Results\n## Conclusions\n## Plain language summary\n## Keywords","[{\"question\":\"What was the main objective of the study on miR-190b in ER+ breast cancer?\",\"answer\":\"The study aimed to further define the role of miR-190b in ER+ breast cancer and to identify its clinically relevant targets in breast cancer.\"},{\"question\":\"How did the researchers identify miR-190b targets in ER+ breast cancer?\",\"answer\":\"They used Cancer Genome Atlas data for gene expression and clinical information, and used the ER+ cell line T-47D with biotin-labeled miR-190b immunoprecipitation followed by RNA sequencing; Western blot confirmed a target.\"},{\"question\":\"What is the relationship between miR-190b, RFWD3 expression, and patient outcomes?\",\"answer\":\"miR-190b targets RFWD3, leading to lower RFWD3 protein expression. Lower RFWD3 is associated with better overall survival in Luminal A patients, while this association is not observed in Luminal B patients.\"}]","MicroRNA-190b Targets RFWD3 in Estrogen Receptor–Positive Breast Cancer - Research Article | PDF",1790019699,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/80d1fd9608665fe844108d4f35abcfa7.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f21a51c26d33762f090a21dd3de8dc02.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/19823222f7465e5f987ca1edfd6f5f52.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/466694d99ded5935c16b2133a8c96170.webp",980,1385]